






















Filed • Approved

 antibody  protein  small molecule

As of Dec.31, 2017

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology		KFN321 Darbepoetin Alfa Injection	Long-Acting Erythropoiesis Stimulating Agent	Renal Anemia (on Dialysis)	NDA in preparation in CN	Kirin-Amgen	
				Renal Anemia	Filed in ID		
		KRN1493 Cinacalcet Hydrochloride Oral	Calcium Receptor Agonist	Secondary Hyperparathyroidism	Filed in BN	Licensed from NPS	
		©KHK7580 Evocalcet Oral	Calcium Receptor Agonist	Secondary Hyperparathyroidism	Filed in JP	Licensed from Mitsubishi Tanabe Pharma	
Oncology		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Cutaneous T-cell Lymphoma	Filed in US Filed in EU Filed in JP	In-House	POTELLIGENT® Additional Indication, Dosage and Administration
		Granisetron Patch	5-HT ₃ Serotonin Receptor Antagonist	Chemotherapy induced Nausea and Vomiting	Filed in MY		Licensed from Solasia Pharma
Immunology /Allergy		©KHK4563 Benralizumab Injection	Anti-IL-5 Receptor Humanized Antibody	Asthma	Filed in JP	In-House	POTELLIGENT® Jointly Developed with AstraZeneca/MedImmune NDA holder is AstraZeneca
		KHK4827 Brodalumab Injection	Anti-IL-17 Receptor A Fully Human Antibody	Psoriasis	Filed in TW Filed in TH Filed in SG Filed in MY	Kirin-Amgen	
Central Nervous System		KW-6002 Istradefylline Oral	Adenosine A _{2A} Receptor Antagonist	Parkinson's Disease	NDA in preparation in US	In-House	
Other		©KRN23 Burosumab Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia (XLH)	Filed in EU Filed in US	In-House	Human Antibody-Producing Technology Jointly Developed with Ultragenyx in US and EU

Phase II, Phase III








Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks	
Nephrology		©RTA 402 Bardoxolone Methyl Oral	Antioxidant Inflammation Modulator	CKD in Patients with Type 2 Diabetes	Phase II in JP	Licensed from Reata		
		©KHK7580 Evocalcet Oral	Calcium Receptor Agonist	Hypercalcemia In Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism	Phase III in JP	Licensed from Mitsubishi Tanabe Pharma		
Oncology		©KHK2375 Entinostat Oral	HDAC Inhibitor	Breast Cancer	Phase II in JP	Syndax		
		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Adult T-cell Leukemia/Lymphoma	Phase II in US, EU and others	In-House	POTELLIGENT®	
Immunology /Allergy		©KHK4083 Injection	Anti-OX40 Fully Human Antibody	Ulcerative Colitis	Phase II in US, EU and others	In-House	POTELLIGENT® Human Antibody-Producing Technology	
		©KHK4563 Benralizumab Injection	Anti-IL-5 Receptor Humanized Antibody	Asthma Chronic Obstructive Pulmonary Disease (COPD) Eosinophilic Chronic Rhinosinusitis (ECRS)	Phase III in JP and KR Phase III in JP Phase II in JP	In-House	POTELLIGENT® Jointly Developed with AstraZeneca/MedImmune	
		KHK4827 Brodalumab Injection	Anti-IL-17 Receptor A Fully Human Antibody	Psoriasis Axial Spondyloarthritis (axSpA)	Phase III in KR Phase III in JP, KR and TW		Kirin-Amgen	
		©ASKP1240 Bleselumab Injection	Anti-CD40 Fully Human Antibody	Recurrence of Focal Segmental Glomerulosclerosis (FSGS) in <i>de novo</i> kidney transplant recipients	Phase II in US		In-House	Human Antibody-Producing Technology Jointly Developed with Astellas
	Central Nervous System		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	HTLV-1 associated myelopathy (HAM)	Phase III in JP	In-House	POTELLIGENT®
		©KW-6356 Oral	Adenosine A _{2A} Receptor Antagonist	Parkinson's Disease	Phase II in JP	In-House		
Other		©KRN23 Burosumab Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia (XLH) in adult patients X-linked Hypophosphatemia (XLH) in pediatric patients Tumor Induced Osteomalacia (TIO)/Epiderma l Nevus Syndrome (IENS)	Phase III in US, CA, EU, JP and KR Phase III in US, CA, EU, AU, JP and KR Phase II in US Phase II in JP and KR	In-House	Human Antibody-Producing Technology Jointly Developed with Ultragenyx in US and EU	
		AMG531 Romiplostim Injection	Thrombopoietin Receptor Agonist	Aplastic Anemia Idiopathic (Immune) Thrombocytopenic Purpura	Phase II / III in JP and KR Phase III in CN		Kirin-Amgen	

 Updated since Sep. 30th, 2017 (Area, Stage, Filed, Approved, etc.)
 New Molecular Entity

Ph I

 antibody
  protein
  small molecule





As of Dec. 31, 2017

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		©KHK2455 Oral	IDO 1 Inhibitor	Solid Tumor	Phase I in US	In-House	Combination with KW-0761
		©KHK2823 Injection	Anti-CD123 Fully Human Antibody	Cancer	Phase I in UK	In-House	POTELLIGENT [®] Human Antibody-Producing Technology
		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Solid Tumor	Phase I in US	In-House	POTELLIGENT [®] Combination with Durvalumab/Tremelimumab (Jointly Developed with AstraZeneca) Combination with Docetaxel
					Phase I / II in US		Combination with PF-05082566 (Jointly Developed with Pfizer)
				Phase I in JP		Combination with Nivolumab (Jointly Developed with Ono Pharmaceutical)	
Immunology /Allergy		©KHK4083 Injection	Anti-OX40 Fully Human Antibody	Ulcerative Colitis Atopic Dermatitis	Phase I in JP Phase I in JP	In-House	POTELLIGENT [®] Human Antibody-Producing Technology
		KHK4827 Brodalumab Injection	Anti-IL-17 Receptor A Fully Human Antibody	Autoimmune Disease	Phase I in JP	Kirin-Amgen	
Central Nervous System		©KHK6640 Injection	Anti-Amyloid Beta Peptide Antibody	Alzheimer's Disease	Phase I in EU Phase I in JP	Licensed from Immunas Pharma	
Others		KW-3357 Antithrombin Gamma Injection	Recombinant Human Antithrombin	Disseminated Intravascular Coagulation, Congenital Antithrombin Deficiency	Phase I in EU	In-House	



 Updated since Sep. 30th, 2017 (Area, Stage, Filed, Approved, etc.)
 New Molecular Entity

Updated since Sep. 30th, 2017 (Area, Stage, Filed, Approved, etc.)


Filed • Approved

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Cutaneous T-cell Lymphoma	Filed in US Filed in EU Filed in JP	In-House	POTELLIGENT [®] Additional Indication, Dosage and Administration
Immunology /Allergy		KHK4827 Brodalumab Injection	Anti-IL-17 Receptor A Fully Human Antibody	Psoriasis	Filed in MY	Kirin-Amgen	
Central Nervous System		KW-6002 Istradefylline Oral	Adenosine A _{2A} Receptor Antagonist	Parkinson's Disease	NDA in preparation in US	In-House	
Other		©KFN23 Burosumab Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia (XLH)	Filed in US	In-House	Human Antibody-Producing Technology Jointly Developed with Ultragenyx in US and EU


Phase II, Phase III

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology		©KHK7580 Evocalcet Oral	Calcium Receptor Agonist	Hypercalcaemia In Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism	Phase III in JP	Licensed from Mitsubishi Tanabe Pharma	
Oncology		©KHK2375 Entinostat Oral	HDAC Inhibitor	Breast Cancer	Phase II in JP	Syndax	

Phase I

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Immunology /Allergy		KHK4827 Brodalumab Injection	Anti-IL-17 Receptor A Fully Human Antibody	Autoimmune Disease	Phase I in JP	Kirin-Amgen	

Terminated

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		©ARQ 197 Tivantinib Oral	c-Met Inhibitor	Hepatocellular Cancer	Phase III in JP	Licensed from ArQuile	